Heart rate lowering therapy for acute myocarditis
Value of Heart Rate Lowering Therapy in Acute Myocarditis
This study is testing if a heart rate-lowering medication called Ivabradine can help people with myocarditis feel better and improve their symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Assiut) |
| Trial ID | NCT06312891 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of heart rate lowering therapy, specifically using Ivabradine, in patients diagnosed with myocarditis who do not exhibit left ventricular dysfunction. The focus is on understanding the short-term benefits of this pharmacological approach in managing symptoms and improving outcomes. Participants must meet specific criteria, including age and confirmed diagnosis through cardiac imaging. The study aims to provide insights into the therapeutic value of heart rate management in this condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed myocarditis and no left ventricular dysfunction.
Not a fit: Patients with rheumatic carditis, connective tissue diseases, or those with coronary artery disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve recovery and management of symptoms in patients with myocarditis.
How similar studies have performed: There is limited information on similar studies, making this approach relatively novel in the context of myocarditis treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults: ≥18 years of age. * Presentation: at least one of the following: * Myopericarditis/ACS-like * MINOCA * Arrhythmias: brady or tachyarrhythmias. * Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically). * TTE: LVEF\>40% * CMR-confirmed myo(peri)carditis (Lake Louise criteria) Exclusion Criteria: * • Rheumatic carditis. * Connective tissue diseases (-ve ANA). * Cancer chemotherapy. * Toxicity from immunotherapy. * Vaccine-related myocarditis. * Presence of coronary artery disease. * Peripartum (occurring during the last month of pregnancy or within 5 months after delivery) * ECG: atrial fibrillation/flutter. * Resuscitated sudden death. * Early/initial phase of decompensated heart failure. * Tamponade complicating pericarditis unless successfully managed.
Where this trial is running
Assiut
- Heart Hospital — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: sara mahmoud
- Email: saramahmoud199783@gmail.com
- Phone: 01016862195
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.